Amwell Stock Jumps 54.5% in Three Months, Trades at 0.4X P/S
Amwell’s stock has climbed 54.5% over the last three months, outstripping peers Hims & Hers’ 52.9% decline, Veeva’s 32.9% drop and Inspire Medical’s 25.7% fall. The company trades at a forward 12-month price-to-sales ratio of 0.4X, well below the medical-services peer average of 3.7X.
1. Recent Share Price Performance
Over the past three months, Amwell’s shares have risen 54.5%, significantly outperforming Hims & Hers’ 52.9% decline, Veeva Systems’ 32.9% drop and Inspire Medical’s 25.7% fall. This surge reflects shifting investor sentiment toward telehealth platforms with potential for recurring subscription revenue.
2. Valuation Metrics
Amwell is trading at a forward 12-month price-to-sales ratio of 0.4X, marking the lowest valuation among its medical-services peers. This steep discount to the industry average of 3.7X highlights the market’s cautious stance despite recent share gains.